(Reuters) - Eli Lilly and Co said on Tuesday it would spin off its Elanco animal health business and take it public.
The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. REUTERS/Vincent Kessler/Files
Lilly will retain a stake of less than 20 percent and expects to complete the initial public offering during the second half of the year, the company said in a statement.
Reporting by Tamara Mathias in Bengaluru; Editing by Supriya Kurane
Our Standards:The Thomson Reuters Trust Principles.
0 : 0
- narrow-browser-and-phone
- medium-browser-and-portrait-tablet
- landscape-tablet
- medium-wide-browser
- wide-browser-and-larger
- medium-browser-and-landscape-tablet
- medium-wide-browser-and-larger
- above-phone
- portrait-tablet-and-above
- above-portrait-tablet
- landscape-tablet-and-above
- landscape-tablet-and-medium-wide-browser
- portrait-tablet-and-below
- landscape-tablet-and-below